Condition: Granulomatosis With Polyangiitis · Sponsor: Assistance Publique - Hôpitaux de Paris
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab to induce clinical and serological remission in patients with relapsing PR3-ANCA granulomatosis with polyangiitis.
This description comes directly from the study's public registry record.
Benjamin TERRIER, PhD · 01 58 41 14 61 · benjamin.terrier@aphp.fr
Karima MESBAHI-IHADJADENE · 01 58 41 33 82 · karima.mesbahi@aphp.fr
Always discuss trial participation with your own doctor first.
| Service de Médecine Interne, Centre de reference "Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques" | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06940661